Effect of a Single Preoperative Dose of Sublingual Misoprostol on Intraoperative Blood Loss During Total Abdominal Hysterectomy
Phase 3
- Conditions
- Bleeding during hysterectomy.Intraoperative and postprocedural complications and disorders of genitourinary system, not elsewhere classified
- Registration Number
- IRCT20180821040844N1
- Lead Sponsor
- Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 132
Inclusion Criteria
Patient who were Nominated for Abdominal Hysterectomy due to Benign Gynecologic Disease
Exclusion Criteria
Misoprostol Contraindication
Malignant Gynecologic Disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ?The amount of bleeding during surgery. Timepoint: during surgery (from incision until suturing) and immediately after surgery. Method of measurement: Sum of the measuring the suctioned blood with the absorbed blood in sterile gauzes (assessing the weight difference between bloody gauzes and dry ones).
- Secondary Outcome Measures
Name Time Method Post-operation hemoglobin. Timepoint: 24 hours after surgery. Method of measurement: Blood sample (g/dl).
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain misoprostol's effect on intraoperative blood loss during total abdominal hysterectomy?
How does sublingual misoprostol compare to standard uterotonic agents in reducing surgical bleeding in IRCT20180821040844N1?
Which biomarkers correlate with reduced intraoperative blood loss in misoprostol-treated hysterectomy patients?
What adverse events are associated with preoperative sublingual misoprostol in phase III abdominal hysterectomy trials?
Are synthetic prostaglandins or hemostatic agents being evaluated as alternatives to misoprostol for genitourinary surgical bleeding?